Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Open-Label Treatment Protocol of the Human Anti-TNF Monoclonal Antibody Adalimumab in Patients With Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab

NCT00338650 is registered in ClinicalTrials.gov with Abbott as lead sponsor.

NCT NCT00338650
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00338650 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Open-Label Treatment Protocol of the Human Anti-TNF Monoclonal Antibody Adalimumab in Patients With Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab
Lead sponsor
Abbott
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2006
Completion date
May 31, 2007
Enrollment
1,000
Sites
97

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease